{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:21:21Z","timestamp":1788182481452,"version":"build-2803163510"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunoglobulin M (IgM) multiple myeloma (MM) is an exceptionally rare plasma cell malignancy, representing &lt;0.5% of all MM cases. The diagnosis presents significant challenges due to overlapping clinical features with Waldenstr\u00f6m macroglobulinemia and other IgM-producing lymphoproliferative disorders. We report a 64-year-old female who presented with a 3-week history of persistent lower back pain. Initial laboratory evaluation revealed mild anemia (hemoglobin 9.2 g\/dL), markedly elevated serum IgM levels (5,070 mg\/dL), and a prominent M-spike (3.09 g\/dL) on serum protein electrophoresis. Immunofixation electrophoresis confirmed monoclonal IgM lambda gammopathy with an abnormal free light chain ratio (0.12). Beta-2 microglobulin was elevated at 2,413 ng\/mL, suggesting a high tumor burden. Bone marrow trephine biopsy demonstrated 25% plasma cell infiltration with lambda light chain restriction on\n                    <jats:italic toggle=\"yes\">in situ<\/jats:italic>\n                    hybridization. Positron emission tomography computed tomography imaging revealed multiple hypermetabolic lytic skeletal lesions throughout the axial and appendicular skeleton. The absence of lymphoplasmacytic infiltration, hepatosplenomegaly, or hyperviscosity symptoms and negative MY88 and negative Cxcr4 mutation effectively differentiated this presentation from Waldenstr\u00f6m macroglobulinemia. The patient was treated with a bortezomib-based regimen including bortezomib, lenalidomide, and dexamethasone, along with supportive therapy including bisphosphonates and thromboprophylaxis. This case highlights the diagnostic complexity of IgM MM and emphasizes the importance of comprehensive evaluation, including bone marrow examination, advanced imaging, and detailed protein studies for accurate differentiation from other IgM-producing disorders. Early recognition and appropriate treatment with novel agents may improve outcomes in this rare myeloma variant.\n                  <\/jats:p>","DOI":"10.4103\/aam.aam_356_25","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T11:00:17Z","timestamp":1766401217000},"page":"1313-1317","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Immunoglobulin M Multiple Myeloma: Case Report of a Rare Variant of Multiple Myeloma with Diagnostic and Treatment Challenges"],"prefix":"10.4103","volume":"25","author":[{"given":"Vikram","family":"Vikhe","sequence":"first","affiliation":[{"name":"Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarthak","family":"Mangal","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishana","family":"Dalvi","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahanaa","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Department of General Medicine, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"R1-20260831","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20260831","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"key":"R3-20260831","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","article-title":"Global burden of multiple myeloma: A systematic analysis for the global burden of disease study 2016","volume":"4","author":"Cowan","year":"2018","journal-title":"JAMA Oncol"},{"key":"R4-20260831","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"R5-20260831","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blad\u00e9","year":"1996","journal-title":"Br J Haematol"},{"key":"R6-20260831","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1158\/1078-0432.CCR-19-1507","article-title":"BRAF and DIS3 mutations associate with adverse outcome in a long-term follow-up of patients with multiple myeloma","volume":"26","author":"Boyle","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R7-20260831","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/leu.2009.174","article-title":"International myeloma working group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"R8-20260831","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1182\/blood-2010-10-299529","article-title":"Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3","volume":"117","author":"Dimopoulos","year":"2011","journal-title":"Blood"},{"key":"R9-20260831","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"R10-20260831","doi-asserted-by":"crossref","first-page":"v52","DOI":"10.1093\/annonc\/mdx096","article-title":"Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Moreau","year":"2017","journal-title":"Ann Oncol"},{"key":"R11-20260831","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"R12-20260831","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13256-020-02380-2","article-title":"Immunoglobulin M (IgM) multiple myeloma versus Waldenstr\u00f6m macroglobulinemia: Diagnostic challenges and therapeutic options: Two case reports","volume":"14","author":"Elba","year":"2020","journal-title":"J Med Case Rep"},{"key":"R13-20260831","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.21845","article-title":"IgM multiple myeloma: Disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia","volume":"85","author":"Schuster","year":"2010","journal-title":"Am J Hematol"},{"key":"R14-20260831","doi-asserted-by":"crossref","first-page":"1073274817744448","DOI":"10.1177\/1073274817744448","article-title":"Case report of igm multiple myeloma: Diagnosing a rare hematologic entity","volume":"25","author":"Bonilla-Valent\u00edn","year":"2018","journal-title":"Cancer Control"},{"key":"R15-20260831","first-page":"215","article-title":"Prognostic importance of beta-2-microglobulin in multiple myeloma","volume":"44","author":"Avil\u00e9s","year":"1992","journal-title":"Rev Invest Clin"},{"key":"R16-20260831","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1200\/JCO.1986.4.1.80","article-title":"Prognostic factors and staging in multiple myeloma: A reappraisal","volume":"4","author":"Bataille","year":"1986","journal-title":"J Clin Oncol"},{"key":"R17-20260831","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"R18-20260831","doi-asserted-by":"crossref","first-page":"5220","DOI":"10.1182\/blood.V112.11.5220.5220","article-title":"IgM multiple myeloma: A rare subtype highly sensitive to lenalidomide","volume":"112","author":"Moreno-Aspitia","year":"2008","journal-title":"Blood"},{"key":"R19-20260831","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"R20-20260831","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/bjh.18295","article-title":"Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: A practical review","volume":"199","author":"McCaughan","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_356_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:00:59Z","timestamp":1788181259000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_356_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_356_25","relation":{},"ISSN":["1596-3519","0975-5764"],"issn-type":[{"value":"1596-3519","type":"print"},{"value":"0975-5764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,15]]},"assertion":[{"value":"2025-07-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}